O'Shaughnessy Kevin M
Clinical Pharmacology Unit, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.
Clin Sci (Lond). 2008 Jun;114(11):661-77. doi: 10.1042/CS20070369.
Cardiovascular disease is the leading cause of death worldwide and premature arterial stiffening is a key contributor to this risk. A large body of evidence now points to arterial stiffness as an independent predictor of cardiovascular events. Stiffness can be assessed by a number of indices and is itself affected by factors including mean arterial pressure, vascular smooth muscle tone and structural elements in the vessel wall, such as elastin and collagen. In addition, aging, hypertension, diabetes and hypercholesterolaemia all exacerbate the stiffening process. Stiffness is highly heritable but, despite a clear genetic basis, the precise molecular pathways regulating stiffness are poorly understood. The present review provides an overview of the current literature and examines the evidence that links genetic factors to arterial wall properties. Although the findings support stiffness as a complex genetic trait, the precise nature of the genes contributing to this are still largely unknown. There are a number of candidate genes and many of these could potentially affect the structure and function of the arterial wall. Indeed, it is likely that genes involving signalling pathways and control of the vessel wall matrix will be as important as those involved in the renin-angiotensin system, adrenergic and other vasoactive systems. Identifying the genes involved is important, since it may suggest new biomarkers as well as provide novel drug targets to reduce arterial stiffness. Current pharmacological intervention is simply to reduce blood pressure, but there are emerging therapies; for example, targeted at breaking collagen cross-links or preventing their formation, which are promising new strategies to reduce arterial stiffness and its associated cardiovascular risk.
心血管疾病是全球主要的死因,动脉过早硬化是导致这一风险的关键因素。现在大量证据表明动脉僵硬度是心血管事件的独立预测指标。僵硬度可以通过多种指标进行评估,其本身也受到多种因素的影响,包括平均动脉压、血管平滑肌张力以及血管壁中的结构成分,如弹性蛋白和胶原蛋白。此外,衰老、高血压、糖尿病和高胆固醇血症都会加剧硬化过程。僵硬度具有高度遗传性,尽管有明确的遗传基础,但调节僵硬度的精确分子途径仍知之甚少。本综述概述了当前的文献,并审视了将遗传因素与动脉壁特性联系起来的证据。尽管研究结果支持僵硬度是一种复杂的遗传性状,但导致这种性状的基因的确切性质在很大程度上仍然未知。有许多候选基因,其中许多可能会影响动脉壁的结构和功能。事实上,涉及信号通路和血管壁基质控制的基因可能与参与肾素 - 血管紧张素系统、肾上腺素能和其他血管活性系统的基因同样重要。识别相关基因很重要,因为这可能会揭示新的生物标志物,并提供新的药物靶点以降低动脉僵硬度。目前的药物干预只是降低血压,但也有新出现的疗法;例如,针对破坏胶原蛋白交联或防止其形成的疗法,这些都是降低动脉僵硬度及其相关心血管风险的有前景的新策略。